NCT00550927View on ClinicalTrials.gov

Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

March 31, 2010

Study Completion Date

September 30, 2012

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
BIOLOGICAL

bevacizumab

DRUG

enzastaurin hydrochloride

OTHER

diagnostic laboratory biomarker analysis

OTHER

pharmacological study

Trial Locations (1)

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Eli Lilly and Company

INDUSTRY

NCT00550927 - Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer | Biotech Hunter | Biotech Hunter